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ABSTRACT
OBJECTIVE
To investigate the clinical outcomes of patients 
who underwent cardioversion compared with those 
who did not have cardioverson in a large dataset 
of patients with recent onset non-valvular atrial 
fibrillation.
DESIGN
Observational study using prospectively collected 
registry data (Global Anticoagulant Registry in the 
FIELD-AF—GARFIELD-AF).
SETTING
1317 participating sites in 35 countries.
PARTICIPANTS
52 057 patients aged 18 years and older with newly 
diagnosed atrial fibrillation (up to six weeks’ duration) 
and at least one investigator determined stroke risk 
factor.
MAIN OUTCOME MEASURES
Comparisons were made between patients who 
received cardioversion and those who had no 
cardioversion at baseline, and between patients 
who received direct current cardioversion and 
those who had pharmacological cardioversion. 
Overlap propensity weighting with Cox proportional 
hazards models was used to evaluate the effect 
of cardioversion on clinical endpoints (all cause 
mortality, non-haemorrhagic stroke or systemic 
embolism, and major bleeding), adjusting for baseline 
risk and patient selection.
RESULTS
44 201 patients were included in the analysis 
comparing cardioversion and no cardioversion, and 
of these, 6595 (14.9%) underwent cardioversion at 
baseline. The propensity score weighted hazard ratio 
for all cause mortality in the cardioversion group 
was 0.74 (95% confidence interval 0.63 to 0.86) 
from baseline to one year follow-up and 0.77 (0.64 
to 0.93) from one year to two year follow-up. Of the 
6595 patients who had cardioversion at baseline, 
299 had a follow-up cardioversion more than 48 days 
after enrolment. 7175 patients were assessed in 
the analysis comparing type of cardioversion: 2427 
(33.8%) received pharmacological cardioversion and 
4748 (66.2%) had direct current cardioversion. During 
one year follow-up, event rates (per 100 patient years) 
for all cause mortality in patients who received direct 
current and pharmacological cardioversion were 1.36 
(1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively.
CONCLUSION
In this large dataset of patients with recent onset 
non-valvular atrial fibrillation, a small proportion 
were treated with cardioversion. Direct current 
cardioversion was performed twice as often as 
pharmacological cardioversion, and there appeared 
to be no major difference in outcome events 
for these two cardioversion modalities. For the 
overall cardioversion group, after adjustments for 
confounders, a significantly lower risk of mortality was 
found in patients who received early cardioversion 





After anticoagulation treatment for stroke prevention 
has been prescribed to appropriate patients (those with 
increased risk of stroke), there are two main treatment 
approaches for atrial fibrillation. One approach is to 
try and restore sinus rhythm, which can be achieved 
by direct current or pharmacological cardioversion. 
Rhythm control can potentially relieve symptoms 
and prevent progression of atrial fibrillation1 and 
left atrial remodelling.2 The other treatment option 
is to allow atrial fibrillation to continue but to 
control the ventricular rate (rate control). Several 
randomised controlled trials have shown that this 
treatment strategy is non-inferior to rhythm control 
when considering endpoints such as stroke rates and 
mortality.3-9 Previous studies also indicate that rates 
of hospital admission for rate control are lower than 
those for rhythm control.4 Guidelines in Europe and 
America support both strategies but stress the need 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
For decades direct comparisons of rhythm control and rate control strategies in 
patients with atrial fibrillation have favoured rate control
More recent results from real world observations on the effect of rhythm control 
versus rate control on clinical endpoints (such as strokes and mortality) in 
patients with new onset atrial fibrillation are inconclusive
WHAT THIS STUDY ADDS
A small proportion of patients were treated with cardioversion
Direct current cardioversion was performed twice as often as pharmacological 
cardioversion, and no major difference in outcome events was found for these 
two modalities
A lower risk of mortality was observed for patients with newly diagnosed atrial 
fibrillation who underwent early cardioversion compared with patients who did 
not have early cardioversion
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for better knowledge about their efficacy and safety.10 
11 However, the recently reported Early Treatment 
of Atrial Fibrillation for Stroke Prevention Trial 
(EAST-AFNET 4)12 showed that early rhythm control 
was superior to guideline mandated management, 
which consisted largely of rate control until or unless 
symptoms became refractory.
The Global Anticoagulant Registry in the FIELD-AF 
(GARFIELD-AF) is a worldwide prospective study of 
adult patients with newly diagnosed non-valvular atrial 
fibrillation.13 14 The registry includes information on 
baseline patient characteristics, rate of interventions 
such as cardioversions, and clinical outcomes. Only 
patients with first time onset of atrial fibrillation within 
six weeks were included, and so a high proportion 
might be eligible for an early rhythm control strategy. 
These data assess the use of cardioversion in daily 
clinical practice and might provide important 
information for clinicians treating patients with recent 
onset non-valvular atrial fibrillation.
In the current study, we aimed to investigate the 
characteristics of patients who received cardioversion 
treatment at baseline versus those who did not, and 
to assess types of cardioversion performed. We also 
describe the associations between cardioversion 
and clinical outcomes in a large dataset of patients 




GARFIELD-AF is an international registry of adult 
patients with newly diagnosed non-valvular atrial 
fibrillation with at least one additional risk factor for 
stroke. Patients from 35 countries were prospectively 
enrolled into five consecutive cohorts of approximately 
10 000 patients with intended two year follow-up. A 
total of 52 057 patients were enrolled. The registry 
excluded patients with a transient and reversible 
cause of atrial fibrillation and those for whom 
follow-up was not possible. The sites were randomly 
selected and when this did not generate the required 
number of sites in a given country, the national lead 
investigators were asked to recommend sites to make 
up the numbers (18 of 1317 sites). The sites represent 
different care settings in each participating country 
(office based practice; hospital departments including 
neurology, cardiology, geriatrics, internal medicine, 
and emergency; anticoagulation clinics; and general 
or family practice). Outcomes are investigator reported, 
but a comprehensive audit and quality control system 
that includes onsite audits and remote quality control 
measures was enacted in GARFIELD-AF.
Data collection
Data for the present analysis were extracted from the 
GARFIELD-AF registry in June 2019. Five independent, 
prospective cohorts were included from 2010 to 2016. 
Data were collected from electronic case report forms, 
which were designed by Dendrite Clinical Systems 
(Henley-on-Thames, UK). The coordinating centre of 
the GARFIELD-AF database is the Thrombosis Research 
Institute (London, UK). Patients were contacted at four 
monthly intervals by telephone or postal mail. Data 
were examined for completeness and accuracy by 
the coordinating centre. In accordance with the study 
protocol, 20% of all data submitted electronically were 
monitored against source documentation.15
Content and definitions
Comparisons were made between patients who 
received cardioversion and those who had no 
cardioversion at baseline, and between those 
who received direct current cardioversion and 
pharmacological cardioversion throughout the study. 
Baseline cardioversion was defined as a cardioversion 
that was reported at baseline or that occurred within 
48 days after enrolment to allow for adequate 
anticoagulation treatment for at least three weeks 
before cardioversion. Patients who received more than 
one cardioversion during follow-up were evaluated 
according to the first type of cardioversion received. 
Cardioversion type was evaluated by considering 
cardioversions that occurred at any time during 
follow-up (type of cardioversion was only reported in 
the follow-up forms).
At the time of diagnosis, data on clinical 
characteristics, medical history, cardiovascular risk 
profile, type of atrial fibrillation, care setting specialty 
and treatment choice were collected. We applied the 
GARFIELD-AF risk calculator for measures of stroke, 
bleeding, and mortality risks; this represents the 
expected occurrence of each event within two years 
of enrolment.16 The CHA2DS2-VASc score (congestive 
heart failure, hypertension, age >75, diabetes, stroke or 
transient ischaemic attack, vascular disease, age >65, 
sex category) was also calculated for risk of stroke.17 
Atrial fibrillation types were defined according to the 
European Society of Cardiology guidelines.11 Heart 
failure included patients with current congestive heart 
failure or a history of the condition, or those with left 
ventricle ejection fraction <40%. Vascular disease was 
defined as peripheral artery disease or coronary artery 
disease. During follow-up, data on the occurrence of 
non-haemorrhagic stroke or systemic embolism, major 
bleeding, and all cause mortality were obtained.
Non-haemorrhagic stroke or systemic embolism was 
defined as a composite of ischaemic stroke, unknown 
type stroke, and systemic embolism. Major bleeding 
was classified by investigators according to the 
International Society on Thrombosis and Haemostasis 
definition. Major bleeds, including intracranial bleeds, 
were defined as a combined endpoint of haemorrhagic 
stroke and any major bleed. Minor or non-major 
clinically relevant bleeds that required transfusion, 
that occurred in a critical site, or were fatal bleeds were 
reclassified as major bleeds.
Statistical analysis
Continuous baseline variables are expressed as 
median (interquartile range) and categorical variables 
as frequency and percentage. Clinical endpoints of 
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the study were all cause mortality, non-haemorrhagic 
stroke or systemic embolism, and major bleeding. We 
describe the occurrence of a clinical outcome by using 
the number of events, event rate per 100 person years, 
and 95% confidence interval. Person year rates were 
estimated using a Poisson model. We only considered 
the first occurrence of each event.
We calculated the effect of baseline cardioversion on 
clinical endpoints by using a Cox proportional hazards 
model with a propensity method of overlap weighting 
to balance covariates in the population. This newly 
developed method of overlap propensity weighting 
avoids excluding patients (as with matching) and 
gives the most weight to propensities where equipoise 
exists. This method overlaps weights and optimises the 
efficiency of comparisons by defining the population 
with the most overlap in the covariates between 
treatment groups. This scheme eliminates the potential 
for outlier weights by avoiding a weight based on a 
ratio calculation using values bounded by 0 and 1. 
Therefore, when using overlap weights, many of the 
concerns about the assessment and the trimming of the 
weights are eliminated.18 We applied the same method 
to the comparison of cardioversion techniques.
We used the following variables in the propensity 
model and supplementary list 1 gives a detailed 
description of the variables: country and cohort 
enrolment, sex, age, ethnicity, type of atrial 
fibrillation, care setting specialty and location, heart 
failure, acute coronary syndromes, vascular disease, 
carotid occlusive disease, previous stroke, transient 
ischaemic attack or systemic embolism, previous 
bleeding, venous thromboembolism, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate 
to severe chronic kidney disease, dementia, 
hyperthyroidism, hypothyroidism, current smoking, 
heavy alcohol consumption, body mass index, heart 
rate, systolic and diastolic blood pressure at diagnosis, 
baseline anticoagulation, and antiplatelet use. Figures 
S1 and S2 give absolute standardised differences for all 
these variables. Figures S3 and S4 show the distribution 
of the propensity score for the two comparisons.
We estimated the effects of baseline cardioversion 
for all studied outcomes at one and two years 
after enrolment. Baseline cardioversions include 
cardioversions that occurred within 48 days from 
enrolment. To limit the possible immortal time bias 
caused by this selection, we also performed landmark 
analyses for the all cause mortality outcome 48 and 
365 days after enrolment. These analyses were not 
replicated for non-fatal events because of the small 
number of events.
We carried out two sensitivity analyses. The 
first analysis included patients with a follow-up 
cardioversion after enrolment but within 48 days; 
time at risk was taken from cardioversion instead of 
enrolment. Secondly, we conducted a time dependent 
analysis; time at risk started from enrolment and we 
modified the baseline cardioversion status within 48 
days when a cardioversion occurred. Tables S1 and 
S2 present the results from these analyses. Negligible 
differences were found compared with the main 
analyses.
Event occurrence by cardioversion type 
(pharmacological or direct current) were reported 
as the number of events and the event rate per 100 
person years from time of follow-up cardioversion up 
to one year. We did not exclude patients with missing 
values from the study, but single imputation was 
applied to estimate the baseline cardioversion effect. 
We performed the imputation procedure assuming 
arbitrary missing patterns and by applying a fully 
conditional specification method that assumes a joint 
distribution for all variables. The fully conditional 
specification method involves two steps: the filled 
in phase, where a discriminant function is used for 
binary variables, logistic for ordinal and regression for 
continuous variables, filling in sequentially over the 
variables, one at a time; and the imputation phase. 
These steps are iterated to obtain final estimates. 
Table S3 presents the proportion of missing data. Data 
analysis was performed at the Thrombosis Research 
Institute with SAS software, version 9.4 (SAS Institute, 
Cary, NC, USA).
Patient and public involvement
Members of the study group have performed regular 
meetings with patient representatives about ongoing 
scientific projects and activities. There was no explicit 
funding for patient and public involvement and 
because this was a multinational study, we did not 
have enough resources for involvement of patient 
representatives in all countries that were involved in 
the study.
Results
The analyses comparing cardioversion or no 
cardioversion comprised 44 201 patients after 
we excluded those with unknown cardioversion 
information (n=1277), those with permanent or 
unknown type of atrial fibrillation (n=6546), and those 
with unavailable follow-up information (n=33; fig 1). 
Of the 6595 patients with a baseline cardioversion, 299 
had a follow-up cardioversion that occurred more than 
48 days after enrolment. In the analysis comparing 
type of cardioversion, 7175 patients were assessed: 
2427 were treated with pharmacological cardioversion 
and 4748 with direct current cardioversion.
Baseline patient characteristics: cardioversion 
versus no cardioversion
Patients who received cardioversion were younger 
(median age 67.0 years, interquartile range 58.0-74.0) 
than those who did not have cardioversion (71.0, 63.0-
78.0, P<0.001; table 1) and a higher proportion had a 
CHA2DS2-VASc score of ≤1 (21.1% v 14.4%, P<0.001). 
The proportion of patients with previous stroke, 
transient ischaemic attack, or systemic embolism in 
the cardioversion group was around half that reported 
in the non-cardioversion group (6.8% v 11.9%, 
P<0.001), while occurrence of previous bleeding 
appeared similar between the two groups (2.3% v 
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2.6%, P=0.13). The GARFIELD-AF risk scores of death, 
stroke, and major bleeding were all numerically lower 
in the cardioversion group.
Table S4 presents the distribution of symptoms at 
atrial fibrillation diagnosis by cardioversion or no 
cardioversion at baseline. Patients who underwent 
cardioversion were more likely to be symptomatic 
(85.8% v 73.9%, P<0.001). Table S5 presents the 
adjunctive treatment results. Antiarrhythmic drugs 
were taken by 48% of patients in the cardioversion 
group and 28% in the non-cardioversion group 
(P<0.001). Ablation was performed in 1.7% of patients 
in the cardioversion group and 1.0% in the non-
cardioversion group (P=0.005). Table S6 gives the 
baseline cardioversion distribution by country.
Baseline patient characteristics: pharmacological 
versus direct current cardioversion
The pharmacological cardioversion group had a 
higher proportion of several comorbidities, including 
history of heart failure (26.0% v 21.8%, P<0.001) and 
vascular disease (32.7% v 19.9%, P<0.001; table 1). 
In contrast, among patients who had pharmacological 
cardioversion, 6.9% had a left ventricle ejection 
fraction ≤40% compared with 15.4% for those 
who had direct current cardioversion (P<0.001). 
Most patients in both groups had a CHA2DS2-VASc 
score ≥1 (96.7% and 95.8% for pharmacological 
cardioversion and direct current cardioversion, 
respectively, P=0.08). At the beginning of the study, 
anticoagulation treatment was given less often to 
patients in the pharmacological cardioversion group 
than to those in the direct current cardioversion 
group (57.6% v 82.8%, P<0.001). The proportion 
of patients who were treated with pharmacological 
cardioversion was high in Ukraine, China, and Mexico 
(>70%), while few patients received this treatment in 
the United States, Singapore, the UK, Sweden, and 
Norway (<10%; table 2).
Patient outcomes: cardioversion versus no 
cardioversion
The mortality event rates per 100 person years (95% 
confidence interval) from baseline to two year follow-
up were 2.52 (2.26 to 2.81) in the cardioversion group 
and 3.87 (3.73 to 4.02) in the non-cardioversion group 
(P<0.001). After adjusting for differences in baseline 
risk, the propensity score weighted hazard ratio for 
all cause mortality in the cardioversion group was 
0.74 (0.63 to 0.86, P<0.001) from baseline to one 
year follow-up, 0.77 (0.64 to 0.93, P=0.008) from one 
year to two year follow-up, and 0.75 (0.67 to 0.85, 
P<0.001) from baseline to two year follow-up. The 
weighted hazard ratio for cardioversion from baseline 
to two year follow up was 0.66 (0.54 to 0.82, P<0.001) 
for cardiovascular mortality and 0.91 (0.75 to 1.09, 
P=0.30) for non-cardiovascular mortality.
In the cardioversion group, the event rate for non-
haemorrhagic stroke or systemic embolism during two 
year follow-up was 0.79 per 100 person years (0.65 
to 0.96) compared with 1.03 (0.96 to 1.11) for those 
who did not receive this treatment (P=0.01). For major 
bleeds, the event rates were 0.84 (0.69 to 1.01) and 1.02 
(0.95 to 1.10), respectively (P=0.05). No statistically 
significant beneficial effect of baseline cardioversion 
was observed for non-fatal outcomes after propensity 
score weighting. Table 3 and figure 2 depict the event 
rates and risk estimates for selected time periods for 
the two groups. Figure 3 provides adjusted cumulative 
survival probabilities and propensity score weighted 
hazard ratios for baseline cardioversions versus no 
cardioversion. From the analysis stratified by the 
presence of symptoms, no major differences in the 
effect of cardioversion emerged between patients 
who were symptomatic and those without symptoms 
(tables S7 and S8).
The analysis stratified by heart failure showed 
similar rates for all cause mortality in patients with 
and without heart failure. For non-haemorrhagic 
stroke or systemic embolism and major bleeding, the 
uncertainty around the estimates is too wide to identify 
any evidence of possible differences (tables S9 and 
S10).
Patient outcomes: pharmacological versus direct 
current cardioversion
Within one year of cardioversion, the mortality 
event rate per 100 person years was 1.70 (95% 
confidence interval 1.35 to 2.14) for patients treated 
with pharmacological cardioversion compared with 
1.36 (1.13 to 1.64) among those treated with direct 
current cardioversion (P=0.14). The rates for non-
haemorrhagic stroke or systemic embolism were 0.50 




Patients with available cardioversion information
50 780
Permanent or unavailable type of atrial fibrillation
6546








No baseline conversion (85.1%)
37 606
Fig 1 | Flowchart for selection of study population. GARFIELD-AF=Global Anticoagulant 
Registry in the FIELD-AF. *Baseline cardioversion was defined as cardioversion that was 
reported at baseline or that occurred within 48 days after enrolment
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(0.33 to 0.76) and 0.47 (0.34 to 0.65), respectively 
(P=0.84), and for major bleeds 0.55 (0.36 to 0.82) 
and 0.64 (0.48 to 0.84), respectively (P=0.55; table 
4). After adjusting for differences in baseline risk, the 
propensity score weighted hazard ratio for all cause 
mortality in the pharmacological cardioversion group 
Table 1 | Baseline characteristics by baseline cardioversion and cardioversion type. Data are numbers (percentages) unless stated otherwise
Baseline characteristics







Direct current  
(n=4748) P value*
Sex
      Male 20 689 (55.0) 3856 (58.5) <0.001 1259 (51.9) 3057 (64.4) <0.001
      Female 16 917 (45.0) 2739 (41.5) 1168 (48.1) 1691 (35.6)
Age (years), median (IQR) 71.0 (63.0-78.0) 67.0 (58.0-74.0) <0.001 66.0 (58.0-75.0) 67.0 (59.0-74.0) 0.83
Ethnicity
      White 22 012 (60.1) 5024 (77.9) <0.001 1857 (78.6) 3925 (85.9) <0.001
      Hispanic/Latino 2450 (6.7) 294 (4.6) 158 (6.7) 114 (2.5)
      Asian 11 493 (31.4) 893 (13.9) 288 (12.2) 416 (9.1)
      Afro-Caribbean/mixed/other 662 (1.8) 236 (3.7) 59 (2.5) 114 (2.5)
Body mass index, median (IQR) 26.7 (23.8-30.5) 27.9 (24.9-32.0) <0.001 27.7 (24.8-32.0) 28.7 (25.6-32.7) <0.001
Systolic blood pressure (mm Hg), median (IQR) 131.0 (120.0-145.0) 130.0 (120.0-145.0) 0.04 130.0 (120.0-146.0) 132.0 (120.0-146.0) 0.85
Diastolic blood pressure (mm Hg), median (IQR) 80.0 (70.0-88.0) 80.0 (70.0-90.0) <0.001 80.0 (70.0-90.0) 80.0 (74.0-90.0) <0.001
Pulse (beats per min), median (IQR) 83.0 (70.0-103.0) 95.0 (74.0-122.0) <0.001 92.0 (72.0-126.0) 95.0 (77.0-120.0) 0.62
Type of atrial fibrillation
      Persistent 6291 (16.7) 1298 (19.7) <0.001 294 (12.1) 1222 (25.7) <0.001 
      Paroxysmal 12 303 (32.7) 1680 (25.5) 834 (34.4) 676 (14.2)
      New onset (unclassified) 19 012 (50.6) 3617 (54.8) 1299 (53.5) 2850 (60.0)
Care setting specialty at diagnosis
      Internal medicine, neurology, geriatrics 7779 (20.7) 1089 (16.5) <0.001 452 (18.6) 782 (16.5) <0.001 
      Cardiology 24 831 (66.0) 4733 (71.8) 1692 (69.7) 3160 (66.6)
      Primary care, general practice 4996 (13.3) 773 (11.7) 283 (11.7) 806 (17.0)
Care setting location at diagnosis
      Hospital 22 194 (59.0) 3989 (60.5) <0.001 1506 (62.1) 2666 (56.1) <0.001
       Office, anticoagulation clinic, thrombosis 
centre
11 458 (30.5) 1276 (19.3) 315 (13.0) 1314 (27.7)
      Emergency department 3954 (10.5) 1330 (20.2) 606 (25.0) 768 (16.2)
Medical history
      Heart failure 8117 (21.6) 1553 (23.5) <0.001 631 (26.0) 1036 (21.8) <0.001
      Acute coronary syndromes 3984 (10.6) 786 (11.9) 0.001 335 (13.8) 458 (9.7) <0.001
      Vascular disease† 9184 (24.6) 1688 (25.7) 0.04 789 (32.7) 942 (19.9) <0.001
      Carotid occlusive disease 1090 (2.9) 180 (2.8) 0.45 78 (3.3) 106 (2.3) 0.01
      Venous thromboembolism 964 (2.6) 175 (2.7) 0.66 60 (2.5) 139 (2.9) 0.27
      Previous stroke, transient ischaemic attack, 
systemic embolism
4462 (11.9) 444 (6.8) <0.001 190 (7.9) 363 (7.7) 0.80
      Previous bleeding 967 (2.6) 149 (2.3) 0.13 60 (2.5) 105 (2.2) 0.48
      Hypertension 28 687 (76.5) 4947 (75.2) 0.03 1914 (79.0) 3507 (74.1) <0.001
      Hypercholesterolemia 15 102 (41.5) 2889 (45.1) <0.001 1138 (48.7) 1970 (42.8) <0.001
      Diabetes 8485 (22.6) 1278 (19.4) <0.001 462 (19.0) 919 (19.4) 0.75
      Cirrhosis 223 (0.6) 34 (0.5) 0.45 14 (0.6) 22 (0.5) 0.53
      Moderate to severe CKD 3914 (10.8) 557 (8.7) <0.001 231 (9.8) 393 (8.5) 0.07
      Dementia 566 (1.5) 46 (0.7) <0.001 19 (0.8) 17 (0.4) 0.02
Heavy alcohol consumption 765 (2.4) 134 (2.4) 0.91 35 (1.6) 122 (3.3) <0.001
Current smoker 3785 (11.1) 765 (12.7) <0.001 292 (12.8) 541 (12.8) 0.10
Treatment
      New oral anticoagulants±antiplatelets 9825 (26.5) 2388 (36.9) <0.001 649 (27.5) 1882 (40.2) <0.001 
      Vitamin K antagonists±antiplatelets 14 376 (38.7) 2189 (33.9) 710 (30.1) 1992 (42.6)
      Antiplatelets only 8251 (22.2) 1110 (17.2) 671 (28.4) 416 (8.9)
      None 4650 (12.5) 779 (12.0) 330 (14.0) 390 (8.3)
CHA2DS2-VASc score, median (IQR) 3.0 (2.0-4.0) 3.0 (2.0-4.0) <0.001 3.0 (2.0-4.0) 3.0 (2.0-4.0) <0.001
CHA2DS2-VASc score ≤1 5336 (14.4) 1373 (21.1) <0.001 418 (17.4) 1086 (23.1) <0.001
HAS-BLED score, median (IQR)‡ 1.0 (1.0-2.0) 1.0 (1.0-2.0) <0.001 1.0 (1.0-2.0) 1.0 (0.0-2.0) <0.001
GARFIELD-AF death score, median (IQR)§ 4.6 (2.5-8.6) 3.9 (2.3-7.0) <0.001 4.1 (2.5-7.5) 3.7 (2.3-6.4) <0.001
GARFIELD-AF stroke score, median (IQR)¶ 1.6 (1.1-2.4) 1.3 (0.9-1.9) <0.001 1.4 (1.0-2.1) 1.2 (0.9-1.8) <0.001
GARFIELD-AF bleeding score, median (IQR)** 1.6 (1.0-2.4) 1.3 (0.9-2.1) <0.001 1.3 (0.8-2.1) 1.3 (0.8-2.1) 0.02
CHA2DS2-VASc=congestive heart failure, hypertension, age >75, diabetes, stroke or transient ischaemic attack, vascular disease, age >65, sex category; GARFIELD-AF=Global Anticoagulant 
Registry in the FIELD-AF; HAS-BLED=hypertension, abnormal renal or liver function, stroke, bleeding tendency or predisposition, labile INR, elderly (>65 years), drugs or alcohol; INR=international 
normalised ratio; IQR=interquartile range.
*Calculated using two independent sample t tests or Wilcoxon-Mann-Whitney tests for continuous variables, as appropriate, and χ2 or Fisher exact test for categorical variables, as appropriate.
†Defined as peripheral artery disease or coronary artery disease.
‡The risk factor labile INRs is not included in HAS-BLED score because it is not collected at baseline. As a result, maximum HAS-BLED score at baseline is 8 (not 9).
§Represents expected risk of mortality within two years.
¶Represents expected risk of non-haemorrhagic stroke or systemic embolism within two years.
**Represents expected risk of major bleeding within two years.
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compared with the direct current cardioversion group 
was 1.27 (0.89 to 1.80, P=0.18).
Discussion
In this study of a large sample of patients with recent 
onset atrial fibrillation who were followed up for 
two years, a small number received cardioversion at 
baseline. Importantly, we found that patients treated 
with baseline cardioversion appeared to have a 
significantly lower mortality risk during follow-up after 
adjustment for known confounders (event rates per 
100 patient years 2.52 v 3.87, weighted hazard ratio 
0.75, 95% confidence interval 0.67 to 0.85, P<0.001). 
Our analyses show that most patients treated with 
cardioversion receive a direct current approach. Event 
rates for all cause mortality in these patients, given 
differences in baseline risk, appear similar to those for 
patients who received pharmacological cardioversion.
Of the 44 201 patients included in the analysis of 
cardioversion versus no cardioversion at baseline, 
an attempt was made to restore sinus rhythm in only 
14.9%. Given that the study population consisted 
of patients with newly diagnosed atrial fibrillation, 
this number seems low. Studies suggest that recent 
onset atrial fibrillation responds favourably to rhythm 
control10 11 19 20 because a long duration of atrial 
fibrillation could make cardioversion less likely to 
succeed.21-24 Additionally, patients may experience 
symptom relief after rhythm control even when not 
obviously symptomatic before cardioversion.25 26 
Therefore, international guidelines suggest a rhythm 
control strategy should be considered with the aim 
of reducing atrial fibrillation related symptoms 
and improving quality of life.11 However, several 
randomised controlled trials comparing rate control 
and rhythm control strategies have not found 
significant differences in mortality rates or other 
adverse outcomes, but a higher hospital rate has been 
reported for rhythm control.3-9 In the recently published 
EAST-AFNET 412 that included patients diagnosed one 
year or less before enrolment, a rhythm control strategy 
was associated with a lower risk of cardiovascular 
outcomes and a similar hospital admission rate 
compared with usual care among patients with early 
atrial fibrillation and cardiovascular conditions. Our 
observations support a rhythm control strategy being 
Table 2 | Distribution of cardioversion type by country
Country Pharmacological (row %) Direct current (row %)
Ukraine (n=519) 78.8 21.2
China (n=97) 77.3 22.7
Mexico (n=48) 72.9 27.1
Russia (n=370) 69.5 30.5
United Arab Emirates (n=87) 63.2 36.8
Chile (n=83) 62.6 37.4
India (n=32) 62.5 37.5
Egypt (n=85) 60.0 40.0
Japan (n=149) 58.4 41.6
Argentina (n=136) 53.7 46.3
Hungary (n=243) 51.8 48.2
Italy (n=253) 45.4 54.6
Brazil (n=154) 44.2 55.8
Spain (n=312) 41.7 58.3
Canada (n=133) 39.9 60.1
France (n=287) 33.5 66.5
Thailand (n=25) 32.0 68.0
Switzerland (n=22) 31.8 68.2
Poland (n=584) 30.1 69.9
Turkey (n=107) 26.2 73.8
Czech Republic (n=374) 25.9 74.1
Austria (n=45) 24.4 75.6
Denmark (n=137) 24.1 75.9
Australia (n=214) 19.2 80.8
Belgium (n=670) 16.1 83.9
Germany (n=374) 15.8 84.2
South Korea (n=265) 15.1 84.9
South Africa (n=169) 13.6 86.4
Finland (n=121) 13.2 86.8
Netherlands (n=315) 10.2 89.8
United States (n=193) 9.8 90.2
Singapore (n=13) 7.7 92.3
United Kingdom (n=260) 7.3 92.7
Sweden (n=234) 2.6 97.4
Norway (n=65) 1.5 98.5
Table 3 | Event rates (per 100 person years), crude and propensity score weighted hazard ratios* by baseline 
cardioversion within one and two year follow-up
Outcome, time 
period (days)
No baseline cardioversion Baseline cardioversion
Crude HR (95% CI)†
Propensity score  
weighted HR (95% CI)†Events Rate (95% CI) Events Rate (95% CI)
All cause mortality
0-48 291 5.92 (5.28 to 6.65) 40 4.64 (3.40 to 6.32) 0.78 (0.56 to 1.09) 0.83 (0.59 to 1.17)
49-365 1284 4.10 (3.88 to 4.33) 145 2.60 (2.21 to 3.06) 0.64 (0.54 to 0.75) 0.71 (0.60 to 0.85)
366-730 1130 3.35 (3.16 to 3.56) 131 2.14 (1.81 to 2.55) 0.64 (0.53 to 0.77) 0.77 (0.64 to 0.93)
0-365 1575 4.35 (4.14 to 4.57) 185 2.87 (2.49 to 3.32) 0.66 (0.57 to 0.77) 0.74 (0.63 to 0.86)
0-730 2705 3.87 (3.73 to 4.02) 316 2.52 (2.26 to 2.81) 0.65 (0.58 to 0.73) 0.75 (0.67 to 0.85)
Non-haemorrhagic stroke or systemic embolism
0-365 443 1.23 (1.12 to 1.35) 61 0.95 (0.74 to 1.22) 0.78 (0.59 to 1.01) 0.92 (0.69 to 1.23)
0-730 716 1.03 (0.96 to 1.11) 98 0.79 (0.65 to 0.96) 0.76 (0.62 to 0.94) 0.93 (0.75 to 1.17)
Major bleeding
0-365 476 1.32 (1.21 to 1.45) 65 1.01 (0.80 to 1.29) 0.77 (0.59 to 1.00) 0.78 (0.59 to 1.02)
0-730 709 1.02 (0.95 to 1.10) 104 0.84 (0.69 to 1.01) 0.82 (0.67 to 1.01) 0.85 (0.69 to 1.06)
HR=hazard ratio.
*Obtained using an overlap weighted Cox model. Variables included in weighting scheme are as follows: country and cohort enrolment, sex, age, 
ethnicity, type of atrial fibrillation, care setting specialty and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid 
occlusive disease, previous stroke, transient ischaemic attack or systemic embolism, previous bleeding, venous thromboembolism, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate to severe chronic kidney disease, dementia, hyperthyroidism, hypothyroidism, current smoking, 
heavy alcohol consumption, body mass index, heart rate, systolic and diastolic blood pressure at diagnosis, baseline anticoagulation, and antiplatelet 
use.
†Reference: no baseline cardioversion.
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beneficial for patients with recent onset non-valvular 
atrial fibrillation.
In our dataset, direct current cardioversion 
was performed twice as often as pharmacological 
cardioversion. Previous data support the concept that 
direct current cardioversion has a higher success rate 
than pharmacological cardioversion,22 27 with quicker 
onset of effect, less monitoring, and fewer hospital 
admissions.28 29 Therefore, direct current cardioversion 
has emerged as the method of choice, although from 
a patient perspective, pharmacological cardioversion 
is often perceived as less frightening. Because of 
an increased risk of severe side effects, the options 
available for pharmacological cardioversion in patients 
with heart failure and reduced ejection fraction are 
limited. Amiodarone is often preferred but has a later 
onset of effect than other antiarrhythmic drugs.11 26 30 31 
Therefore, when patients are considered for a rhythm 
control strategy, direct current cardioversion might be 
more appropriate. In our dataset, a higher proportion 
of patients in the direct current cardioversion group 
were observed to have a left ventricle ejection fraction 
<40%. Additionally, we believe that a driver for the 
difference between these groups might be that this 
form of cardioversion is preferred by clinicians, in 
accordance with current guidelines, for patients who 
are haemodynamically unstable.10 11 Nevertheless, the 
pharmacological cardioversion group had a higher 
proportion of patients with coronary artery disease.
Patients in GARFIELD-AF had at least one non-
specified risk factor for stroke, and in our analysis 
of cardioversion type, we found that more than 
95% in both cardioversion groups had a CHA2DS2-
VASc score ≥1. However, only 57.6% of patients who 
received pharmacological cardioversion were treated 
with anticoagulants at baseline. The number was 
higher in the direct current cardioversion group in 
which 82.8% received anticoagulants. Most of our 
sample had an increased risk of stroke, and so it 
might have been more beneficial for patient outcome 
if a higher anticoagulation rate had been achieved. 
Anticoagulation treatment was registered at baseline. 
For some patients the choice of cardioversion could 
have come later and anticoagulation treatment might 
have been started at that point.
Considerable variations were found in choice of 
cardioversion modality from country to country. 
Patient comorbidities, treatment choice, and follow-up 
opportunities in the different countries might therefore 
have contributed to the differences observed between 
the two groups in the cardioversion modality analysis.
In the analysis comparing cardioversion with no 
cardioversion we found that fewer patients in the 
cardioversion group experienced a severe clinical 
event (all cause mortality, non-haemorrhagic stroke 
or systemic embolism, or major bleed) in the first year 
and from baseline to two year follow-up. Patients 
who received cardioversion had a lower risk profile at 
baseline. To better evaluate the effect of cardioversion, 
weighted hazard ratio prediction models were used. 
After adjusting for baseline risk, we found that there 
was a significant difference in mortality among the 
two treatment groups, within one and two years of 
follow-up. The lower all cause mortality rate was 
driven by less cardiovascular mortality. Risks of non-
haemorrhagic stroke or systemic embolism, and 
major bleeding trended in the same direction. In two 
sensitivity analyses (the first with time at risk changed 
from time of inclusion to time of cardioversion; the 
second, with time at risk from time of inclusion 
but with baseline cardioversion status modified if 
cardioversion occurred), only negligible differences 
were found compared with the main analysis. Our 
study reported significantly lower rates of mortality 
in the cardioversion group and supports the use of 
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Fig 2 | Crude and propensity score weighted hazard ratios by baseline cardioversion 
(reference: no baseline conversion) for selected time periods. Hazard ratios obtained 
by using an overlap weighted Cox model. Variables included in the weighting scheme 
are country and cohort enrolment, sex, age, ethnicity, type of atrial fibrillation, care 
setting speciality and location, congestive heart failure, acute coronary syndromes, 
vascular disease, carotid occlusive disease, previous stroke, transient ischaemic attack 
or systemic embolism, previous bleeding, venous thromboembolism, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate to severe chronic kidney 
disease, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol 
consumption, body mass index, heart rate, systolic and diastolic blood pressure at 
diagnosis, baseline anticoagulation, and antiplatelet use
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Fig 3 | Adjusted cumulative survival probabilities by baseline cardioversion and 
propensity score weighted hazard ratio for baseline cardioversion versus no baseline 
cardioversion (reference)
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Rhythm control strategies were started early after atrial 
fibrillation diagnosis in our study and in EAST-AFNET 
4, which is in contrast to previous studies6-8; this might 
have contributed to the better outcomes reported in the 
rhythm control groups.
There was a trend of lower event rates in our study 
compared with the recently published EAST-AFNET 
4. When considering baseline characteristics, we 
found that patients in GARFIELD-AF (in baseline 
cardioversion and no baseline cardioversion groups) 
appeared to have lower risk profiles than both study 
groups in EAST-AFNET 4. Additionally, EAST-AFNET 
4 had a median follow-up of 5.1 years, while in 
GARFIELD-AF the follow-up was two years. This longer 
observational period subsequently leads to a study 
sample with more aged patients with higher risk (both 
studies only included patients with newly diagnosed 
atrial fibrillation). Therefore, a better risk profile at 
baseline combined with a shorter observational period 
are some potential causes of the lower event rates 
presented in our study. In contrast to EAST-AFNET, the 
Catheter Ablation versus Antiarrhythmic Drug Therapy 
for Atrial Fibrillation (CABANA) study32 reported 
similar mortality rates. Follow-up in the CABANA study 
was longer than in the present study, but baseline 
characteristics appeared comparable.
When we analysed patients who received 
pharmacological or direct current cardioversion, we 
found that the event rates for non-haemorrhagic stroke 
or systemic embolism, and major bleeding within 
the first year of cardioversion were similar in the two 
groups. After adjusting for known confounders, we 
found no significant difference in mortality rates. The 
low number of events made it difficult to obtain robust 
hazard ratio estimates to compare cardioversion type 
effects on other outcomes.
Strengths and limitations of the study
One strength of the GARFIELD-AF registry is the large 
study sample with patients represented from many 
countries, which improves generalisability to real world 
clinical practice. Data in the registry are observational 
and non-randomised, and for any comparisons the 
data had to be adjusted for potential confounding 
baseline factors. Cardioversion was not randomised 
and the rationale for varying treatment decisions is 
unknown; although robust statistical methods were 
used to account for differences between groups, the 
potential for residual confounding cannot be ruled out. 
Although several possible confounders were included 
in the propensity score weighting scheme, we were not 
able to account for factors such as healthier lifestyle, 
better surveillance, and adjunctive treatment. Other 
unrecognised factors might also have influenced the 
results and the application of falsification endpoints 
to check for residual confounding was not deemed 
feasible with the available recorded outcomes.
Information on type of cardioversion was only 
available from the follow-up forms and the modality is 
therefore not known for all cardioversions performed. 
Data on success and duration of a successfully restored 
sinus rhythm were not obtained. The precise treatment 
given for pharmacological cardioversion was not 
collected.
The decision to separate baseline cardioversions 
from follow-up cardioversions at 48 days was based on 
the requirement of previous anticoagulation treatment, 
and therefore this was an arbitrary choice. The analysis 
and the comparison between cardioversion and no 
cardioversion were applied to this group. Therefore, 
the results presented in this study might not be 
generalisable to patients with longer duration of atrial 
fibrillation. In the cardioversion type analysis, event 
rates were too low to calculate adjusted hazard ratios 
for non-fatal events. Therefore, differences in the 
baseline risk profile between the two groups should be 
taken into account when interpreting the results.
Clinical event rates were evaluated after two 
years in the cardioversion versus no cardioversion 
analysis and after one year when analysing the type 
of cardioversion. A longer observation time would be 
valuable when assessing the long-terms effects of the 
different interventions.
Conclusions
In this large dataset of patients with recent onset non-
valvular atrial fibrillation, a small proportion were 
treated with cardioversion. Direct current cardioversion 
was performed twice as often as pharmacological 
cardioversion. No major difference in outcome events 
was observed for these two cardioversion modalities. 
For the overall cardioversion group, after adjusting 
for confounders, a significantly lower risk of mortality 
was found in patients who received cardioversion at 
baseline compared with those who did not receive this 
treatment at baseline.
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